Overview of The Intelligence from The Economist
This episode moves between three sharply different stories: the emerging business of longevity drugs, a fact-check on claims about immigrants and sex crimes in Britain, and a lighter look at the booming world of miniatures. The main theme tying the episode together is how data, incentives, and public imagination shape everything from medicine to politics to hobbies.
The business of longevity drugs
The first segment explores why “living longer” has become a serious commercial idea for pharma and biotech.
Main points
- Interest in anti-ageing science is rising among tech founders, investors, and major pharmaceutical companies.
- High-profile figures such as Dario Amodei, Sam Altman, Jeff Bezos, and Peter Thiel are backing or discussing longevity-related research.
- The industry’s current strategy is not to seek approval for “ageing” itself, since ageing is not recognized as a disease by the FDA.
- Instead, companies are targeting specific age-related diseases first, hoping some drugs will also have broader longevity effects.
Why the sector is attractive
- Huge market potential: If a drug really slowed ageing, the commercial upside could dwarf even the GLP-1 boom.
- Patent cliff pressure: Big Pharma is looking for the next blockbuster as major patents expire toward the end of the decade.
- Biotech partnerships: Large drugmakers are increasingly partnering with smaller, more experimental firms rather than leading the charge themselves.
Examples mentioned
- Eli Lilly + Insilico: a deal potentially worth up to $2.75 billion.
- Novartis + BioAge Labs: a deal worth about $550 million.
- These firms are pursuing “dual-purpose therapeutics” — drugs designed for a known disease, but with longevity benefits in mind.
The caution
- The episode stresses that evidence is still early.
- Most studies have been done in people already sick with specific conditions, not healthy people aiming to extend lifespan.
- Drug development is slow and expensive, and ageing itself takes decades to observe properly in clinical outcomes.
Notable idea
- GLP-1 drugs are the closest existing model: they began as diabetes drugs, became obesity drugs, and are now being explored for broader health benefits that may affect lifespan indirectly.
Fact-checking claims about immigrants and sex crimes
The second segment examines a politically charged claim that Afghan nationals are far more likely than Britons to commit sexual offences.
What the claim said
- A right-wing source claimed Afghan nationals were 22 times more likely to be convicted of sexual offences than British people.
Why that figure is shaky
- It relied on a very weak population estimate for Afghans in England and Wales.
- That estimate came from a small sample and was later discontinued by the ONS due to poor response rates.
What the Economist’s data analysis found
- Using Ministry of Justice and other population data, the team cleaned and adjusted the figures more carefully.
- Key corrections included:
- accounting for age structure,
- excluding children,
- adjusting for the fact that most sexual offences are committed by adult men,
- estimating population changes over time.
Bottom line
- The “22 times” claim is not reliable.
- A more robust estimate suggests Afghan nationals’ conviction rate for sexual offences is about 7 times that of British people — still a disparity, but much smaller than claimed.
Important caveats
- The data measures convictions, not actual offending rates.
- Convictions can be affected by:
- underreporting,
- police detection bias,
- “few bad apples” effects,
- differences in demographic profile and social conditions.
- Ethnicity-based data offers a different picture: South Asian and Middle Eastern groups, including naturalised British citizens, do not show conviction rates dramatically different from white British people.
Key takeaway
- The episode argues for caution with raw crime statistics, especially when they are used to make broad claims about migration and nationality.
The rise of miniatures
The final segment turns to a lighter, more whimsical trend: the growing popularity of miniatures.
What’s happening
- Miniatures are enjoying a major resurgence.
- A convention in Coventry showcased intricate tiny creations, from dollhouses and furniture to tiny food, lighting, and even micro-taxidermy.
- The business side is growing too: retailers have reported sharp sales increases, and attendance at miniature events is rising.
Why people are drawn to them
- Miniatures offer:
- creative control,
- escapism,
- a sense of world-building,
- a hands-on analogue hobby in a digital age.
- The appeal crosses generations:
- teenagers,
- collectors,
- hobbyists,
- older makers constructing elaborate village scenes.
Memorable example
- One group had built a whole tiny village, complete with:
- a pub,
- school,
- church,
- café,
- hairdresser.
- What began as a single cottage had expanded into an entire miniature community.
Takeaway
- Miniatures may be small, but they represent a surprisingly large trend in craft, nostalgia, and escapist creativity.
Overall takeaways
- Longevity drugs are becoming a serious business opportunity, even if real anti-ageing treatments remain years away.
- Data matters: the crime segment shows how misleading statistics can be when population assumptions are weak or incomplete.
- Miniatures reflect a broader cultural appetite for tactile, imaginative, low-tech hobbies that offer a sense of control and calm.